EFLM survey on Alzheimer’s disease Biomarkers

The aim of this survey is to assess the current adopted procedure and promote activities for their improvement and harmonization. Deadline: 15 October 2025

Cerebrospinal fluid (CSF) and blood biomarkers are increasingly used in Alzheimer’s disease (AD) research, but there is an active discussion about the procedures to be adopted in the total testing processes.

To review the current state of the art in the management of the biomarker’s measurements from the European Laboratories in this specific clinical setting, we would like to invite you to take part in the EFLM survey on Alzheimer’s disease Biomarkers.

The survey will be open until 15 October 2025.
It will take approx. 15 minutes to complete the survey

The aim of this survey is to assess the current adopted procedure and promote activities for their improvement and harmonization.

Your laboratory may receive more than one invitation to participate in the survey but we would kindly ask you to make only one submission per laboratory.

This survey is created by the EFLM Committee "Harmonisation" of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Take the survey - https://survey.eflm.eu/index.php/282282?lang=en